James Datin is listed as a director on 15 SEC Form D filings by 7 issuers between Apr 2009 and Jul 2014. Largest by amount reported sold: NovaSom, Inc (Glen Burnie, MD — other health care — 2011–2014; $34.7M reported sold to 18 investors), CLARIENT, INC (Aliso Viejo, CA — other health care — 2009; $29.1M reported sold to 56 investors), NUPATHE INC. (Conshohocken, PA — pharmaceuticals — 2012; $28M reported sold to 20 investors), Quinnova Pharmaceuticals, Inc. (Newtown, PA — pharmaceuticals — 2009–2010; $17.4M reported sold to 18 investors), MOLECULAR BIOMETRICS INC (Norwood, MA — biotechnology — 2010; $12.8M reported sold to 16 investors) and 2 more (all listed below).
What this means A repeat sponsor — 7 separate companies raised money with this person listed as director, over about 5 years. Across those companies the filings report $128.7M sold in total.
Listed alongside Dean Miller (4 shared filings), Franklyn Prendergast (4 shared filings), Jack Reynolds (4 shared filings), LeRoy Metz (4 shared filings), Matthew Malenfant (4 shared filings) and 58 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around James. Each name links to their own page.
1 of the issuers belongs to the sponsor group Sleep (2 issuers, $27.6M reported sold, 2009–2019).
What this means A sponsor group is one team that sets up a new company for each deal. Sleep has 2 companies on file and $27.6M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 15 public filings for James Datin and found 15 differences, 4 worth asking the sponsor about: Amount sold went down between filings; James Datin is no longer listed on the Apr 22, 2016 amendment; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.